NEW YORK (GenomeWeb News) – Rosetta Genomics today announced two collaborations to advance its microRNA-based diagnostic tests.
The Rehovot, Israel-based company has signed agreements with Tel Hashomer Medical Research Infrastructure and Services and Carmel Medical Center, both also based in Israel, to develop and validate Rosetta's miRNA-based tests for indications related to its Gen 3 products.
The Gen 3 tests will focus on cardiovascular disease, neurodegenerative disease, women's health, and early detection of certain cancers. They are designed to leverage miRNA biomarkers found in body fluids, Rosetta said.
Financial and other terms of the deal were not disclosed.
"Our goal is to obtain proof-of-concept data on at least one of our Gen 3 products this year," Kenneth Berlin, president and CEO of Rosetta, said in a statement. "With encouraging preliminary data in two of these Gen 3 indications already, Rosetta will be conducting studies to determine if these results hold up over larger sample sizes."